Biologically defined neuronal synuclein disease as a tool to advance drug development

IF 6.7 1区医学 Q1 NEUROSCIENCES

NPJ Parkinson's Disease Pub Date : 2024-12-20 DOI:10.1038/s41531-024-00845-5

Gennaro Pagano, Tien Dam, Geoffrey A. Kerchner, Wendy R. Galpern, Milton Biagioni, Rajesh Karan, Danna Jennings, M. Judith Peterschmitt, Tania Nikolcheva, Patrik Brundin

引用次数: 0

Abstract

In a recent Viewpoint article (JAMA Neurol. 2024;81:789‒90), Okubadejo et al. raised concerns regarding two recent proposals for biological definitions and staging systems for synucleinopathies (the Neuronal Synuclein Disease Integrated Staging System and SynNeurGe system). While acknowledging these concerns, we provide an alternative perspective—that such frameworks represent important steps forward by allowing biologically defined populations to be targeted with precision treatments that can be accurately evaluated using stage-specific outcomes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Parkinson's Disease Medicine-Neurology (clinical)

CiteScore

9.80

自引率

5.70%

发文量

156

审稿时长

11 weeks

期刊介绍： npj Parkinson's Disease is a comprehensive open access journal that covers a wide range of research areas related to Parkinson's disease. It publishes original studies in basic science, translational research, and clinical investigations. The journal is dedicated to advancing our understanding of Parkinson's disease by exploring various aspects such as anatomy, etiology, genetics, cellular and molecular physiology, neurophysiology, epidemiology, and therapeutic development. By providing free and immediate access to the scientific and Parkinson's disease community, npj Parkinson's Disease promotes collaboration and knowledge sharing among researchers and healthcare professionals.